Introduction {#Sec1}
============

Psoriasis vulgaris is a common skin disorder characterized by focal formation of inflamed, raised plaques that constantly shed scales derived from excessive growth of skin epithelial cells \[[@CR1]\]. The common form of psoriasis is plaque psoriasis, in which patients may have sharply circumscribed, round oval, or nummular plaques \[[@CR2]\]. In most cases, the severity of this disease is mild as limited body surface area is affected \[[@CR3]\]. Mild psoriasis can often be treated with topical agents, although adherence to topical therapy is often suboptimal. Patient satisfaction with topical therapies is low due to frequent relapses, because treatments can be greasy, sticky, and malodorous in application, and can cause staining of clothing and linens \[[@CR4], [@CR5]\]. For this reason, some psoriatic patients constantly seek, especially on the Internet and online forums, new therapies using new or old chemical compounds having antipsoriatic activity; among others, use of sodium bicarbonate (SB) compounds has been suggested. SB or baking soda is the monosodium salt of carbonic acid; its therapeutic properties have been widely studied to demonstrate its effectiveness against several pathologies. In particular, for skin pathologies, it can be employed as an antimicrobial and for treatment of aquagenic pruritus \[[@CR6], [@CR7]\]. In relation to psoriasis, therapy with SB has been investigated in balneotherapy \[[@CR8], [@CR9]\]. Patients subjected to these treatments showed a significant improvement in psoriatic lesions as well as quality of life. However, topical application of SB is an anecdotal remedy, and controlled studies are lacking. The aim of this study is to evaluate whether application of an SB topical product can improve psoriatic lesions, also when performed outside of a comfortable environment such as balneotherapy.

Methods {#Sec2}
=======

Product {#Sec3}
-------

In this study, a galenic SB (Sigma-Aldrich) 30% in lanette wax *N* (BASF Care Creation) (INCI: cetearyl alcohol, sodium cetearyl sulfate) formulation was used \[[@CR10], [@CR11]\].

Study Design {#Sec4}
------------

This single-center, randomized, double-blinded, intraindividual, comparative study enrolled 30 adult patients of both genders. The study was conducted at the Skinlab, Department of Biomedical Sciences, University of Sassari, Italy. All clinical studies were reviewed and approved by the Ethical Committee Local Health Unit 1 (Sassari, Italy). Inclusion criteria were age between 20 and 60 years and symmetric, stable plaque psoriasis on arms, legs, and some patches on the trunk with maximum Psoriasis Area and Severity Index (PASI) score of 10.8. Patients were excluded if they were underage, pregnant or breastfeeding women, had received topical or systemic treatments during the 3 months prior to experiments, or had positive anamnesis for allergic contact dermatitis. Treatment was performed randomly on the left and right side of the body, applying the SB in lanette vax formulation on one side and lanette vax on the other side, while patches on the trunk were not treated. During the first clinical visit to standardize the dose of the two products, which is different for each patient as it is linked to the extension of the patches, we used a Silkidose^®^ (Galderma Laboratories) to indicate to each patient the quantity to apply on the areas to be treated. The patients were instructed to apply the medications twice daily for 28 days with a slight massage until absorption and were prohibited from using any emollient during application. Treatment efficacy was assessed by a blinded investigator based on noninvasive skin analysis and the disease clinical progression indexes---PASI and body surface area (BSA). Before starting the experiment, for noninvasive analysis, three skin reference areas (elbow, knee, and trunk) for each patient were selected: (a) a psoriatic patch treated with galenic SB, (b) a second contralateral psoriatic patch treated with lanette wax *N* (vehicle), and (c) a third psoriatic patch of the trunk not treated, as negative control. Objective measurements were made on these patches. The skin barrier function was evaluated by measuring the transepidermal water loss (TEWL) using a Tewameter^TM^ 300 (Courage + Khazaka Electronic GmbH, Cologne, Germany), and hydration in the stratum corneum was assessed using a Corneometer CM 825 (Courage + Khazaka Electronic GmbH, Cologne, Germany). Skin color was measured using a Mexameter MX 16 (Courage + Khazaka Electronic GmbH, Cologne, Germany). An erythema index was computed from the intensity of the absorbed and reflected light at 568 and 660 nm, respectively \[[@CR12]\]. These devices, specifically the corneometer and tewameter, have already been used to evaluate psoriatic skin and the efficacy of moisturizing \[[@CR13]\]. Few and contradictory studies have measured the skin pH of psoriatic lesions; the authors hypothesized that significantly lower skin pH in psoriatic skin compared with healthy subjects could be a cause or consequence of excess fatty acids \[[@CR14]\]. Instrumental assessments were performed at time *t*0 (baseline) and after 60 min (*t*60m) during the short-term test. During the long-term tests, patients were evaluated after 7 days (*t*7d), 14 days (*t*14d), and 28 days (*t*28d) of continuous application of the product. At each phase of the research, each volunteer was asked not to clean test zones for at least 12 h prior to examination. Before measurements, patients remained for 30 min in an air-conditioned room where the assessment was going to take place with skin reference areas uncovered, to favor acclimatization of the skin to room temperature and humidity conditions. All measurements were performed on central areas of selected patches by the same experimenter. The PASI score was calculated at baseline, *t*7d, *t*14d, and the end of the treatment period. Because this was an intrapatient study, we used a modified PASI that included the upper and lower extremities and trunk only. Patients scored their psoriasis symptoms, including erythema, infiltration, and desquamation, for the test areas (skin surface extremities of the left and right side and skin of the trunk). The sum of the scores was calculated for each parameter, using a similar scoring system to that of the original PASI score, viz. no sign = 0, slight = 1, moderate = 2, severe = 3 \[[@CR15]\]. As only patients with slight to moderate severity of psoriasis were included, the maximum score for each test area was 3.6. The difference between the score sums on the test area was not allowed to be more than 0.50. The local PASI score was evaluated at each visit during the long-term test. The primary efficacy endpoint was the difference in the percent change in the baseline PASI score between the three test areas at week 4. BSA was assessed for a single-area test at each visit during the long-term test.

Statistical Analysis {#Sec5}
--------------------

All results were compared with each baseline measurement by paired *t* tests, or with a nonparametric test (Wilcoxon signed-rank test) when difference means did not have normality characteristics, as verified by Shapiro--Wilk test. All data analyses were performed using Stata SE 15.0 with *p* \< 0.05 considered as statistically significant. All data are expressed as mean ± standard deviation (SD), and beyond measured values, differences versus baseline are reported.

Compliance with Ethical Guidelines {#Sec6}
----------------------------------

All procedures performed in studies involving human participants were in accordance with IntegReview IRB, who granted an exemption from Institutional Review Board oversight in accordance with 45 CFR 46.101(b) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Results {#Sec7}
=======

All subjects completed the study. Their demographic characteristics are reported in Table [1](#Tab1){ref-type="table"}. Baseline disease characteristics were also comparable across the treatment sides (Table [2](#Tab2){ref-type="table"}), and the mean target lesion size was in the range of 12--94 cm^2^. All procedures and clinical analysis were performed under identical environmental conditions, at mean temperature of 22.1 ± 1.7 °C and mean humidity of 55 ± 4%, between 9 a.m. and 2 p.m.Table 1Demographics of volunteers enrolled in the studyDemographic characteristic of patients*N* = 30Dropout*N* = 0Male20 (64%)Female10 (33%)Age (range)26--52 yearsAge (mean ± SD)36.4 ± 9.31 yearsTable 2Summary of baseline patient disease characteristics, mean ± SDDisease characteristicSBVehicleControlModified PASI score3.42 ± 0.363.23 ± 0.462.82 ± 0.59% BSA affected2.4 ± 1.82.5 ± 1.71.9 ± 1.2Size of target lesion (cm^2^)49.7 ± 32.852.1 ± 42.624.6 ± 20.1*SB* random extremities area treated with galenic sodium bicarbonate 30% in lanette wax *N*, *Vehicle* contralateral random extremities area treated only with lanette wax *N*, *Control* trunk area not treated

Efficacy Results: Noninvasive Skin Analysis {#Sec8}
-------------------------------------------

Hydration values of psoriatic patches significantly increased compared with baseline only at 60 min after SB application. Psoriatic patches treated with vehicle showed a similar increase of skin hydration values compared with baseline. Comparisons between these two groups did not show statistically significant differences (*p* = 0527). SB cream applied on psoriatic patches did not modify TEWL and erythema values, in a similar way to vehicle, during short- and long-term tests (Table [3](#Tab3){ref-type="table"}).Table 3Descriptive statistics, mean ± SD, and *p* value for all observed variablesPsoriatic patch treated with SB*t*0*t*60m*t*7d*t*14d*t*30dCorneometric measurement8.19 ± 9.5611.66 ± 11.5\*9.015 ± 10.08.335 ± 8.898.045 ± 8.31TEWL measurement20.82 ± 9.7419.46 ± 7.6620.24 ± 8.3817.68 ± 8.1016.59 ± 7.40Colorimetric E measurement600.8 ± 27.9599.3 ± 27.8593.1 ± 34.4579.0 ± 35.8572.9 ± 30.6Psoriatic patch treated with vehicle*t*0*t*60m*t*7d*t*14d*t*30dCorneometric measurement8.71 ± 6.6810.78 ± 8.75\*9.37 ± 6.2510.47 ± 8.529.78 ± 8.20TEWL measurement21.27 ± 9.7320.33 ± 12.419.95 ± 10.019.21 ± 11.618.65 ± 8.47Colorimetric E measurement595.8 ± 27.2601.2 ± 34.4592.0 ± 28.3585.4 ± 18.8580.1 ± 36.2Psoriatic patch not treated*t*0*t*60m*t*7d*t*14d*t*30dCorneometric measurement6.43 ± 2.766.09 ± 2.485.295 ± 2.436.1 ± 2.817.08 ± 2.84TEWL measurement17.83 ± 4.0119.03 ± 4.3820.83 ± 4.4118.62 ± 3.6119.59 ± 4.95Colorimetric E measurement591.2 ± 35.3598.0 ± 29.8594.3 ± 24.7590.2 ± 32.2585.1 ± 32.2*SB* galenic sodium bicarbonate 30% in lanette wax *N*, *Vehicle* only lanette wax *N*\**p* \< 0.05

Efficacy Results: PASI and BSA {#Sec9}
------------------------------

The change in modified PASI from baseline is presented in Table [4](#Tab4){ref-type="table"}. At day 28, there was a 5.7% decrease in PASI for the SB test area, but as for the BSA score, no significant improvement of psoriatic lesions.Table 4Change of PASI from baseline at each visit, *N* (%)Modified PASI scoreSBVehicleControl*t*7d− 0.07 (− 2.0%)− 0.13 (− 1.3%)− 0.18 (− 2.6%)*t*14d− 0.1 (− 4.0%)− 0.2 (− 4.3%)0.05 (5.21%)*t*28d− 0.2 (− 5.7%)− 0.2 (− 4.0%)− 0.12 (− 1.0%)*SB* random extremities area treated with galenic sodium bicarbonate 30% in lanette wax *N*, *Vehicle* contralateral random extremities area treated only with lanette wax *N*, *Control* trunk area not treated

Discussion {#Sec10}
==========

SB is widely used in medicine to treat numerous diseases, with several applications in the field of internal medicine; in fact, its efficacy when used on a topical basis has been demonstrated in many studies, for instance in treatment of gingivitis \[[@CR16]\], oral hygiene protection \[[@CR17]\], as well as associated with paracetamol in pharyngitis and in interstitial cystitis \[[@CR18], [@CR19]\]. In vitro antimicrobial efficacy against microorganisms such as dermatophytes (*Candida albicans*, *Escherichia coli*, *Staphylococcus aureus* , group B streptococci) has also been studied \[[@CR20], [@CR21]\]. However, for treatment of psoriasis, the only form of SB whose effectiveness has been demonstrated is balneotherapy. Indeed, in literature, after getting wet in a water solution with 350--500 g dissolved SB on alternate days for 3 weeks, 19 subjects showed a significant improvement in psoriatic lesions and, at the same time, quality of life, unlike the placebo group \[[@CR10]\]. Another study might confirm these properties: 30 patients affected by psoriasis were treated at Castellammare of Stabia spa (Napoli, Italy) with mud and baths containing water rich in chloride--sulfide--bicarbonate, coming from mineral springs, showing an improvement in PASI and itchy symptoms after a 12-day treatment \[[@CR9]\]. The cause of this improvement is not clear, so far. It has been hypothesized that the most important factor is the basic pH created by SB dissolved in water, which should have a keratolytic action or play a role in activating some molecules involved in the disease or exert an action on the skin microbiome \[[@CR22]\]. As the skin microbiome is typically altered in psoriasis \[[@CR23]\], some authors showed that psoriatic subjects treated with La Roche-Posay spa water, rich in selenium, had a net improvement in lesions due to changes induced in the microbiome by this water \[[@CR24]\]. As far as the work carried out by Costantino et al. is concerned, the favorable environment of the spas that may have contributed to the clinical improvement of lesions should also be taken into account. Besides, the efficacy of balneotherapy has been well described by several authors \[[@CR25]--[@CR27]\]. However, in these studies, it is not clear how much the psychological benefits associated with balneotherapy affected the improvement of lesions and how much the changes were actually caused by the action of the thermal water. Certainly, these two effects act synergistically, thus causing the regression of cutaneous inflammation. Topical use of SB in other formulations for psoriasis treatment is thus still anecdotal, and there are no studies proving its effectiveness. In some books or on social forums, its use in galenic formulations with castor oil or olive oil is recommended as a natural treatment for considerably thick psoriatic lesions \[[@CR28]\]. The aim of this study is to evaluate the efficacy of SB in a galenic preparation for improving psoriatic lesions. It seemed important to our team to evaluate whether SB is effective even when used independently of balneotherapy performed at a spa or home. Our study aimed to evaluate the ability of a topical SB product to improve cutaneous lesions in subjects affected by psoriasis, but the results obtained in this study should be considered negative. They do not confirm the efficacy of topical SB cream in improving stable psoriatic plaques, untreated with other therapies for at least 3 months. In fact, it was not possible to highlight any improvement of PASI, BSA, erythema, hydration, or TEWL after 28 days of daily treatment. The patches treated with SB, patches treated with the base, and patches not treated remained stable throughout the treatment, and no statistically significant differences were found between the groups analyzed. This lack of response could be linked to the fact that the formulation did not maintain the basic pH after application or the concentration used was insufficient to obtain the expected results.

Limitations {#Sec11}
-----------

This study was conducted on a limited sample of 30 individuals affected by stable plaques of psoriasis vulgaris. To evaluate the results, we used nonparametric tests with post hoc analysis. Such well-designed small studies are valuable but must be interpreted carefully, and data should be used to design larger confirmatory studies. Therefore, this is an exploratory work that offers some important indications for exploration in further studies.

Conclusions {#Sec12}
===========

The 30% SB product tested in this study did not have the ability to improve typical aspects of psoriatic patches after just 1 month of use. However, it should be considered that, due to the small size of the experimental sample considered, further studies are warranted to confirm these results.
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